These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25278770)

  • 1. Profile of selumetinib and its potential in the treatment of melanoma.
    Kim DW; Patel SP
    Onco Targets Ther; 2014; 7():1631-9. PubMed ID: 25278770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
    Patel SP; Kim KB
    Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selumetinib for the treatment of cancer.
    Ciombor KK; Bekaii-Saab T
    Expert Opin Investig Drugs; 2015 Jan; 24(1):111-123. PubMed ID: 25385055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
    Komatsubara KM; Manson DK; Carvajal RD
    Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent MEK inhibition for the treatment of metastatic uveal melanoma.
    Khan S; Patel SP; Shoushtari AN; Ambrosini G; Cremers S; Lee S; Franks L; Singh-Kandah S; Hernandez S; Sender N; Vuolo K; Nesson A; Mundi P; Izar B; Schwartz GK; Carvajal RD
    Front Oncol; 2022; 12():975643. PubMed ID: 36249046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selumetinib-based therapy in uveal melanoma patient-derived xenografts.
    Decaudin D; El Botty R; Diallo B; Massonnet G; Fleury J; Naguez A; Raymondie C; Davies E; Smith A; Wilson J; Howes C; Smith PD; Cassoux N; Piperno-Neumann S; Roman-Roman S; Némati F
    Oncotarget; 2018 Apr; 9(31):21674-21686. PubMed ID: 29774094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
    Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
    Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
    Basken J; Stuart SA; Kavran AJ; Lee T; Ebmeier CC; Old WM; Ahn NG
    Mol Cell Proteomics; 2018 Apr; 17(4):550-564. PubMed ID: 29255136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
    Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
    Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
    Spreafico A; Tentler JJ; Pitts TM; Tan AC; Gregory MA; Arcaroli JJ; Klauck PJ; McManus MC; Hansen RJ; Kim J; Micel LN; Selby HM; Newton TP; McPhillips KL; Gustafson DL; Degregori JV; Messersmith WA; Winn RA; Eckhardt SG
    Clin Cancer Res; 2013 Aug; 19(15):4149-62. PubMed ID: 23757356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
    Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
    Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibitors under development for treatment of non-small-cell lung cancer.
    Kim C; Giaccone G
    Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
    Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
    Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
    Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
    Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.